Rhythm Pharmaceuticals (RYTM) Financial Analysis & Valuation | Quarter Chart
Rhythm Pharmaceuticals (RYTM)
RYTMPrice: $87.38
Fair Value: 🔒
🔒score
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatmen... more
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the developme... more
Description
Shares
| Market Cap | $5.97B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | David Meeker |
| IPO Date | 2017-10-09 | CAGR | — |
| Employees | 283 | Website | www.rhythmtx.com |
| Div. Yield | — | Payout Ratio | -0.02% |
| Buy Back Yield | — | Total Yield | — |
RYTM chart loading...
Fundamentals
Technicals
| Enterprise Value | $5.92B | P/E Ratio | -28.1 |
| Forward P/E | -225.69 | PEG Ratio | — |
| P/S Ratio | 663.15 | P/B Ratio | 749.18 |
| P/CF Ratio | -1021.52 | P/FCF Ratio | -1059.22 |
| EPS | $-3.11 | EPS Growth 1Y | -27.74% |
| EPS Growth 3Y | -14.36% | EPS Growth 5Y | 1.97% |
| Revenue Growth 1Y | 54.92% | Gross Margin | 0.89% |
| Operating Margin | -1.07% | Profit Margin | -1.1% |
| ROE | -1.26% | ROA | -0.38% |
| ROCE | -0.46% | Current Ratio | 4.75 |
| Quick Ratio | 4.75 | Cash Ratio | 0.5 |
| Debt/Equity | 1.01 | Interest Coverage | -8.7 |
| Altman Z Score | 7.11 | Piotroski Score | 4 |